Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Respiration; International Review of Thoracic Diseases|June 28, 2008
Mesothelioma and asbestos-related pleural diseasesLaurent Greillier, Philippe Astoul
Anti-Cancer Drugs|January 26, 2011
Targeted therapies in malignant pleural mesothelioma: a review of clinical studiesLaurent Greillier, Sabine Marco, Fabrice Barlesi
Pharmacogenomics and Personalized Medicine|August 25, 2021
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung CancerAlice Mogenet, Laurent Greillier, Pascale Tomasini
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Review of Anticancer Therapy|July 14, 2022
Nivolumab plus ipilimumab in malignant pleural mesotheliomaCamille Travert, Pascale Tomasini, Laurent Greillier
Bulletin Du Cancer|March 28, 2025
[Recommendations for the management of oligometatic NSCLC]Alice Mogenet, Laurent Greillier, Pascale Tomasini
European Respiratory Review : an Official Journal of the European Respiratory Society|November 17, 2017
Personalised medicine for nonsmall cell lung cancerCéline Mascaux, Pascale Tomasini, Laurent Greillier, et al.
Bulletin Du Cancer|September 26, 2020
[Predictable toxicities with futures immunotherapies or combinations]Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Respiration; International Review of Thoracic Diseases|June 28, 2008
Mesothelioma and asbestos-related pleural diseasesLaurent Greillier, Philippe Astoul
Anti-Cancer Drugs|January 26, 2011
Targeted therapies in malignant pleural mesothelioma: a review of clinical studiesLaurent Greillier, Sabine Marco, Fabrice Barlesi
Pharmacogenomics and Personalized Medicine|August 25, 2021
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung CancerAlice Mogenet, Laurent Greillier, Pascale Tomasini
Therapeutic Advances in Respiratory Disease|June 25, 2016
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Opinion on Biological Therapy|June 9, 2015
Necitumumab for non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Translational Lung Cancer Research|December 4, 2018
The clinical utility of tumor mutational burden in non-small cell lung cancerLaurent Greillier, Pascale Tomasini, Fabrice Barlesi
Expert Review of Anticancer Therapy|July 14, 2022
Nivolumab plus ipilimumab in malignant pleural mesotheliomaCamille Travert, Pascale Tomasini, Laurent Greillier
Bulletin Du Cancer|March 28, 2025
[Recommendations for the management of oligometatic NSCLC]Alice Mogenet, Laurent Greillier, Pascale Tomasini
European Respiratory Review : an Official Journal of the European Respiratory Society|November 17, 2017
Personalised medicine for nonsmall cell lung cancerCéline Mascaux, Pascale Tomasini, Laurent Greillier, et al.
Bulletin Du Cancer|September 26, 2020
[Predictable toxicities with futures immunotherapies or combinations]Alice Mogenet, Pascale Tomasini, Laurent Greillier, et al.
Pageof 16